Frequency Therapeutics Inc

NASDAQ:FREQ   3:59:30 PM EDT
35.83
-1.95 (-5.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.15B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.35 Million
Adjusted EPS-$0.25
See more estimates
10-Day MA$36.21
50-Day MA$31.82
200-Day MA$23.14
See more pivots

Frequency Therapeutics, Inc. Stock, NASDAQ:FREQ

19 PRESIDENTIAL WAY, SUITE 203, WOBURN, MA 01801
United States of America
Phone: 781-315-4600
Number of Employees:

Description

A clinical-stage biotechnology company focused on harnessing the body??s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. Further, these progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ. Our initial therapeutic focus is sensorineural hearing loss, or SNHL, and we believe our PCA platform has the potential to produce a new class of medicines and provide transformative benefits for patients across a wide range of degenerative conditions, including multiple sclerosis, or MS, and diseases of the muscle, gastrointestinal tract, skin, and bone. We intend to continue to identify areas with high unmet need where our PCA platform and novel approach to regenerative medicine could lead to potentially disease-modifying therapeutics that create healthy functional tissues and improve patients?? lives.